Narasimhan Mani - 19 Sep 2024 Form 4 Insider Report for Scienture Holdings, Inc. (SCNX)

Role: President & Co-CEO, Director
Signature: /s/ Kate L. Bechen, as attorney-in-fact for Narasimhan Mani
Issuer symbol: SCNX
Transactions as of: 19 Sep 2024
Net transactions value: $0
Form type: 4
Filing time: 12 Mar 2026, 21:32:38 UTC
Previous filing: 05 Aug 2024
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Narasimhan Mani	President & Co-CEO, Director	C/O SCIENTURE HOLDINGS, INC., 20 AUSTIN BLVD., COMMACK	/s/ Kate L. Bechen, as attorney-in-fact for Narasimhan Mani	12 Mar 2026	0002031317

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SCNX	Common Stock, par value $0.00001	Conversion of derivative security		+1,357,538	+2342%		1,415,515	19 Sep 2024	By Srivatsav, LLC	F1, F2
transaction	SCNX	Common Stock, par value $0.00001	Other		-20,000	-1.4%	$0.000000^*	1,395,515	10 Mar 2025	By Srivatsav, LLC	F2, F3
transaction	SCNX	Common Stock, par value $0.00001	Award		+750,000		$0.000000^*	750,000	14 Apr 2025	Direct	F4
transaction	SCNX	Common Stock, par value $0.00001	Award		+300,000	+40%	$0.000000^*	1,050,000	01 Oct 2025	Direct	F5
transaction	SCNX	Common Stock, par value $0.00001	Award		+500,000	+48%	$0.000000^*	1,550,000	20 Feb 2026	Direct	F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SCNX	Series X Non-Voting Convertible Preferred Stock	Conversion of derivative security		-1,357,538	-100%	$0.000000^*	0	19 Sep 2024	Common Stock, par value $0.00001	1,357,538		By Srivatsav, LLC	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares of the Series X Non-Voting Convertible Preferred Stock, par value $0.00001 per share (the "Series X Preferred Stock"), of Scienture Holdings, Inc. (the "Issuer"), formerly known as TRxADE HEALTH, INC., automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on the twentieth calendar day following the Issuer's mailing of an information statement on Schedule 14C in connection with the closing of the Issuer's previously announced acquisition of Scienture, Inc. on July 25, 2024 pursuant to an Agreement and Plan of Merger. The Series X Preferred Stock had no expiration date.
F2	These securities are owned directly by Srivatsav, LLC ("Srivatsav"). As the Managing Member of Srivatsav, Dr. Narasimhan Mani may be deemed to be the indirect beneficial owner of securities held by Srivatsav. Dr. Mani disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
F3	These shares of Common Stock were transferred by Srivatsav to a designee of NVK Finance, LLC (the "Lender") as consideration for the Lender's consent to certain transactions contemplated by that certain First Amendment to Loan and Security Agreement, dated November 22, 2024, entered into by the Issuer, the Lender, Dr. Mani, and certain other parties thereto.
F4	These shares of restricted Common Stock ("Restricted Shares") vest in two equal annual installments beginning on April 14, 2026.
F5	These Restricted Shares vest in two equal annual installments beginning on October 1, 2026.
F6	On February 20, 2026, the Compensation Committee of the Issuer's Board of Directors approved the award of these Restricted Shares as a discretionary stock bonus for performance in 2025. The Restricted Shares will be issued in three tranches of 166,666 shares on June 1, 2026, 166,667 shares on September 1, 2026, and 166,667 shares on December 1, 2026. Each tranche of Restricted Shares will vest three years following its respective issuance date.